ArticleStem cell research & therapy2025
Constraint-induced movement therapy combined with mesenchymal stem cell transplantation promotes myelination and functional recovery by inhibiting PRKCD/MEK/ERK pathway in hemiplegic cerebral palsy rats.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PRKCD Orchestrates Sevoflurane-Induced Cognitive Dysfunction in Aged Rats by Regulating PINK1/PRKN Mitophagy Pathway.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe core problem of hemiplegic cerebral palsy (HCP) is upper limb motor deficits with high rates of disability. Given the shared goals of stem cell therapy and rehabilitation, this study investigated the synergistic effects of constraint-induced movement therapy (CIMT) and human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) transplantation in promoting motor recovery and elucidates the underlying mechanisms in HCP.
methodsThe rats were allocated to a control group and HCP groups receiving different interventions (CIMT, hUC-MSCs or combination treatment), namely, the Control, HCP, HCP + CIMT, HCP + MSC, and HCP + CIMT + MSC groups. Motor function was evaluated using rotarod duration, grip strength, and forelimb suspension time. Golgi-Cox staining, transmission electron microscopy, immunofluorescence staining, Western blotting, quantitative real-time PCR and label-free proteomic quantification technology were used to measure dendritic/axonal area, myelin integrity, oligodendrocyte (OL)/oligodendrocyte precursor cell (OPC)-associated proteins and PRKCD/MEK/ERK expression in the motor cortex.
resultsRats in the HCP + CIMT + MSC group exhibited improved motor function, increased dendritic spines and branches, enhanced myelin integrity, higher numbers of Olig2
conclusionsCIMT combined with hUC-MSCs transplantation synergistically promoted OPC differentiation into immature OL, induced myelination, and restored motor function in HCP rats, potentially by inhibiting the PRKCD/MEK/ERK pathway. This combined approach expands therapeutic options for HCP and identifies a promising target for future interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.